The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | SCD: Assessing bleeding severity in thrombocytopenic patients
Bart Biemond
• 15 Jun 2019
Bart Biemond, MD, PhD, Academic Medical Centre, Amsterdam, Netherlands, discusses the assessment of bleeding severity in thrombocytopenic, sickle cell anemia patients at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
